var data={"title":"Fluvastatin: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Fluvastatin: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6226?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=fluvastatin-patient-drug-information\" class=\"drug drug_patient\">see &quot;Fluvastatin: Patient drug information&quot;</a> and <a href=\"topic.htm?path=fluvastatin-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Fluvastatin: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F173506\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Lescol XL;</li>\n      <li>Lescol [DSC]</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F173507\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Lescol;</li>\n      <li>Lescol XL</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F173548\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antilipemic Agent, HMG-CoA Reductase Inhibitor</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F173511\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Heterozygous familial and nonfamilial hypercholesterolemia:</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Immediate release: 40 mg once daily in the evening or 40 mg twice daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Extended release: 80 mg once daily (anytime)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Mixed dyslipidemia:</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Immediate release: 40 mg once daily in the evening or 40 mg twice daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Extended release: 80 mg once daily (anytime)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Patients requiring &ge;25% decrease in LDL-C:</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Immediate release: Initial: 40 mg once daily in the evening or 40 mg twice daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Extended release: Initial: 80 mg once daily (anytime)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Patients requiring &lt;25% decrease in LDL-C:</b> Oral: Initial: Immediate release: 20 mg once daily in the evening; may increase based on tolerability and response to a maximum recommended dose of 80 mg/day, given in 2 divided doses (immediate release) or as a single daily dose (extended release)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Prevention of cardiovascular disease/reduce the risk of ASCVD: </b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>ACC/AHA Blood Cholesterol Guideline recommendations (ACC/AHA [Stone 2013]): </b>Adults &ge;21 years:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>\n        <i>Primary prevention:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>LDL-C &ge;190 mg/dL:</i> High-intensity therapy necessary; use alternate statin therapy (eg, atorvastatin, rosuvastatin)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Type 1 or 2 diabetes and age 40 to 75 years:</i> Moderate intensity therapy:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Immediate release: 40 mg twice daily.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Extended release: 80 mg once daily.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Type 1 or 2 diabetes, age 40 to 75 years, and an estimated 10-year ASCVD risk &ge;7.5%:</i> High-intensity therapy necessary; use alternate statin therapy (eg, atorvastatin, rosuvastatin).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Age 40 to 75 years and an estimated 10-year ASCVD risk &ge;7.5%:</i> Moderate- to high-intensity therapy:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Immediate release: 40 mg twice daily or consider using high-intensity statin therapy (eg, atorvastatin, rosuvastatin).</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Extended release: 80 mg once daily or consider using high-intensity statin therapy (eg, atorvastatin, rosuvastatin).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>\n        <i>Secondary prevention:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Patient has clinical ASCVD (eg, coronary heart disease, stroke/TIA, or peripheral arterial disease presumed to be of atherosclerotic origin) or is post-CABG (AHA [Kulik 2015]) <b>and</b>:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Age &le;75 years:</i> High-intensity therapy necessary; use alternate statin therapy (eg, atorvastatin, rosuvastatin).</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Age &gt;75 years or not a candidate for high-intensity therapy: Moderate-intensity therapy:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Immediate release: 40 mg twice daily.</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Extended release: 80 mg once daily.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>NLA Dyslipidemia guideline recommendations (NLA [Jacobson 2015]): </b>Adults &ge;20 years:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Primary or secondary prevention:</i>\n      <b> Note: </b>Treatment initiation using either moderate- or high-intensity statin therapy is recommended in qualifying patients based on ASCVD risk assessment criteria <b>and</b> baseline non-HDL-C and LDL-C values. Dosage should be individualized based on patient characteristics, tolerance to therapy, and with consideration for non-HDL-C and LDL-C treatment goals.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Moderate-intensity therapy (30 to 50% reduction of LDL-C generally):</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Immediate release: 40 mg twice daily.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Extended release: 80 mg once daily.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">High-intensity therapy (&ge;50% reduction of LDL-C generally): Use alternate statin therapy (eg, atorvastatin, rosuvastatin)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>\n        <i>Concomitant use with cyclosporine or fluconazole:</i></b> Immediate release: Do not exceed fluvastatin 20 mg twice daily</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2931789\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=fluvastatin-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Fluvastatin: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Heterozygous familial hypercholesterolemia:</b> Children &ge;10 years and Adolescents &le;16 years: Oral: Initial: 20 mg once daily; may increase every 6 weeks based on tolerability and response to a maximum recommended dose of 80 mg/day, given in 2 divided doses (immediate release) or as a single daily dose (extended release) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concomitant use with cyclosporine or fluconazole:</i></b>  Immediate release: Do not exceed fluvastatin 20 mg twice daily</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F173512\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F173513\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">Mild to moderate renal impairment: No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">Severe renal impairment: There are no dosage adjustments provided in the manufacturer's labeling; use with caution, particularly at doses &gt;40 mg/day (has not been studied).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F173514\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">Use is contraindicated in active liver disease or unexplained transaminase elevations.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22888099\" class=\"block dot drugH1Div\"><span class=\"drugH1\">Dosing: Adjustment for Toxicity</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Severe muscle symptoms or fatigue:</b> Promptly discontinue use; evaluate CPK, creatinine, and urinalysis for myoglobinuria (Stone 2013).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">\n      <b>Mild to moderate muscle symptoms:</b> Discontinue use until symptoms can be evaluated; evaluate patient for conditions that may increase the risk for muscle symptoms (eg, hypothyroidism, reduced renal or hepatic function, rheumatologic disorders such as polymyalgia rheumatica, steroid myopathy, vitamin D deficiency, or primary muscle diseases).  Upon resolution, resume the original or lower dose of fluvastatin. If muscle symptoms recur, discontinue fluvastatin use. After muscle symptom resolution, may then use a low dose of a different statin; gradually increase if tolerated. In the absence of continued statin use, if muscle symptoms or elevated CPK continues after 2 months, consider other causes of muscle symptoms. If determined to be due to another condition aside from statin use, may resume statin therapy at the original dose (Stone 2013).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F173480\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsule, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Lescol: 20 mg [DSC], 40 mg [DSC]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 20 mg, 40 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet Extended Release 24 Hour, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Lescol XL: 80 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 80 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F173465\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F173484\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Oral: Patient should be placed on a standard cholesterol-lowering diet before and during treatment. Administer without regard to meals. Do not break, chew, or crush extended release tablets; do not open immediate-release capsules. Do not administer two 40 mg immediate-release capsules at once.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F173483\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dyslipidemias: </b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Heterozygous familial and nonfamilial hypercholesterolemia and mixed dyslipidemia: Adjunct to diet to reduce elevated total cholesterol (total-C), low-density lipoprotein-cholesterol (LDL-C), triglyceride, and apolipoprotein B (apo-B) levels and to increase HDL-C in adults with primary hypercholesterolemia and mixed dyslipidemia (Fredrickson types IIa and IIb)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Heterozygous familial hypercholesterolemia: As an adjunct to diet to reduce total-C, LDL-C, and apo B levels in children &ge;10 years and adolescents &le;16 years of age (female patients must be at least 1 year postmenarche) with heterozygous familial hypercholesterolemia and an LDL-C that remains &ge;190 mg/dL or &ge;160 mg/dL (with &ge;2 cardiovascular risk factors or a positive family history of premature cardiovascular disease).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Prevention of cardiovascular disease (CVD): </b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Secondary prevention of CVD: To slow the progression of coronary atherosclerosis in patients with coronary heart disease; reduce risk of coronary revascularization procedures in patients with coronary heart disease</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Guideline recommendations:</i></b>Primary and secondary prevention of atherosclerotic cardiovascular disease (ASCVD) to reduce the risk of ASCVD in select adult patients (ACC/AHA [Stone 2013]; ADA 2018a; NLA [Jacobson 2015]). Refer to respective guideline for specific recommendations.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Limitations of use: Has not been studied in conditions where the major abnormality is elevation of chylomicrons, very low-density lipoprotein (VLDL), or intermediate density lipoprotein (IDL) (ie, hyperlipoproteinemia types I, III, IV, or V).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50287199\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Cardiac risk reduction for noncardiac surgery (perioperative therapy); Noncardioembolic stroke/TIA (secondary prevention)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F173556\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Fluvastatin may be confused with fluoxetine, nystatin, pitavastatin</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F173472\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Frequency not always defined. The following adverse events were reported with fluvastatin capsules; in general, adverse reactions reported with fluvastatin extended release tablet were similar, but incidences were lower. &lt;1%/Postmarketing adverse reactions include additional class-related events that were not necessarily reported with fluvastatin therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Headache (9%), fatigue (3%), insomnia (3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Dyspepsia (8%), abdominal pain (5%), diarrhea (5%), nausea (3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Urinary tract infection (2%), cystitis (interstitial; Huang 2015)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Myalgia (5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Sinusitis (3%), bronchitis (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Alopecia, amnesia (reversible), anaphylaxis, angioedema, anorexia, anxiety, arthralgia, arthritis, blurred vision, cataract, changes in nails, chills, cholestatic jaundice, cognitive dysfunction (reversible), decreased libido, depression, dermatomyositis, dizziness, dry mucous membranes, dysgeusia, dyspnea, elevated glycosylated hemoglobin (HbA<sub>1c</sub>), eosinophilia, erectile dysfunction, erythema multiforme, facial paresis, fever, flushing, fulminant hepatic necrosis, gynecomastia, hemolytic anemia, hepatic cirrhosis, hepatic neoplasm, hepatitis, hyperbilirubinemia, hypersensitivity reaction, immune-mediated necrotizing myopathy (IMNM), impairment of extraocular movement, impotence, increased creatine phosphokinase (&gt;10x normal), increased erythrocyte sedimentation rate, increased gamma-glutamyl transferase, increased serum alkaline phosphatase, increased serum glucose, increased serum transaminases, interstitial pulmonary disease, leukopenia, liver steatosis, lupus-like syndrome, malaise, memory impairment (reversible), muscle cramps, myopathy, nodule, ophthalmoplegia, pancreatitis, paresthesia, peripheral nerve palsy, peripheral neuropathy, polymyalgia rheumatica, positive ANA titer, pruritus, psychic disorder, purpura, reversible confusional state, rhabdomyolysis, skin discoloration, skin photosensitivity, skin rash, Stevens-Johnson syndrome, thrombocytopenia, thyroid dysfunction, toxic epidermal necrolysis, tremor, urticaria, vasculitis, vertigo, vomiting, xeroderma</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F173487\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to fluvastatin or any component of the formulation; active liver disease; unexplained persistent elevations of serum transaminases; pregnancy or women planning to become pregnant; breastfeeding</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F173469\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Diabetes mellitus: Increases in HbA<sub>1c</sub> and fasting blood glucose have been reported with HMG-CoA reductase inhibitors; however, the benefits of statin therapy (eg, reduction in the risk of MI or stroke) far outweigh the risk of dysglycemia. If a patient develops diabetes mellitus during therapy, continue use of fluvastatin and encourage patient to adhere to healthy lifestyle regimens (eg, heart healthy dietary pattern, engage in physical activity, achieve and maintain a healthy body weight) (ACC/AHA [Stone 2013]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatotoxicity: Increased AST or ALT has been reported; in most cases, elevations were transient and resolved or improved on continued therapy or after a brief interruption in therapy. Postmarketing reports of fatal and nonfatal hepatic failure have been reported and are rare. If serious hepatotoxicity with clinical symptoms and/or hyperbilirubinemia or jaundice occurs during treatment, interrupt therapy promptly. If an alternate etiology is not identified, do not restart fluvastatin. Possible drug-related hepatitis (rare) was observed that resolved upon discontinuation of treatment. Liver enzyme tests should be obtained at baseline and as clinically indicated and if signs/symptoms of liver injury occur. Ethanol may enhance the potential of adverse hepatic effects; instruct patients to avoid excessive ethanol consumption. Use has been found to be safe in those with active hepatitis C (Kondo 2012; Kurincic 2014).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Myopathy/rhabdomyolysis: Rhabdomyolysis with acute renal failure secondary to myoglobinuria and/or myopathy has been reported; patients should be monitored closely. This risk is dose related and is increased with concurrent use of cyclosporine, erythromycin, or other lipid-lowering medications (eg, fibrates, niacin at doses &ge;1 g/day). Use caution in patients with inadequately treated hypothyroidism, and those taking other drugs associated with myopathy (eg, colchicine); these patients are predisposed to myopathy. Uncomplicated myalgia immune-mediated necrotizing myopathy (IMNM) associated with HMG-CoA reductase inhibitors use has also been reported. Patients should be instructed to report unexplained muscle pain, tenderness, weakness, or brown urine, particularly if accompanied by malaise or fever. Discontinue therapy if markedly elevated CPK levels occur or myopathy is diagnosed/suspected.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Diseases reducing steroidogenesis: Use caution in patients with conditions or on medications that reduce steroidogenesis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment and/or ethanol use: Use with caution in patients who consume large amounts of ethanol or have a history of liver disease. Use is contraindicated in patients with active liver disease or unexplained transaminase elevations.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with renal impairment; these patients are predisposed to myopathy.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly: Use with caution in patients with advanced age; these patients are predisposed to myopathy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Surgical patients: The manufacturer recommends temporary discontinuation for elective major surgery, acute medical or surgical conditions, or in any patient experiencing an acute or serious condition predisposing to renal failure secondary to rhabdomyolysis (eg, sepsis, hypotension, trauma, uncontrolled seizures, severe metabolic, endocrine, or electrolyte disorders). Based on current research and clinical guidelines, HMG-CoA reductase inhibitors should be continued in the perioperative period for noncardiac and cardiac surgery (ACC/AHA [Hillis 2011]; ACC/AHA [Fleisher 2014]). Perioperative discontinuation of statin therapy is associated with an increased risk of cardiac morbidity and mortality.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Drug therapy should be only one component of multiple risk factor intervention in patients at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. In patients with CHD or multiple risk factors for CHD, initiate therapy simultaneously with diet.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hyperlipidemia: Secondary causes of hyperlipidemia should be ruled out prior to therapy.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F173542\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP2C9 (minor), CYP2D6 (minor), CYP3A4 (minor), OATP1B1/SLCO1B1; <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential; <b>Inhibits</b> CYP2C9 (moderate)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F173474\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=8473&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Acipimox: May enhance the myopathic (rhabdomyolysis) effect of HMG-CoA Reductase Inhibitors (Statins).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Asunaprevir: May increase the serum concentration of HMG-CoA Reductase Inhibitors (Statins).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Atazanavir: May increase the serum concentration of Fluvastatin.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bezafibrate: May enhance the myopathic (rhabdomyolysis) effect of HMG-CoA Reductase Inhibitors (Statins). Bezafibrate may increase the serum concentration of HMG-CoA Reductase Inhibitors (Statins). More specifically, bezafibrate may increase the serum concentration of fluvastatin Management: Monitor patients closely for myopathy with concomitant use of bezafibrate and HMG-CoA reductase inhibitors. Concomitant use is contraindicated in patients predisposed to myopathy and alternative therapy should be considered.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Boceprevir: May increase the serum concentration of Fluvastatin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bosentan: CYP2C9 Inhibitors (Moderate) may increase the serum concentration of Bosentan.  Management: Concomitant use of both a CYP2C9 inhibitor and a CYP3A inhibitor or a single agent that inhibits both enzymes with bosentan is likely to cause a large increase in serum concentrations of bosentan and is not recommended.  See monograph for details.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cannabis: CYP2C9 Inhibitors (Moderate) may increase the serum concentration of Cannabis. More specifically, tetrahydrocannabinol serum concentrations may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Carvedilol: CYP2C9 Inhibitors (Moderate) may increase the serum concentration of Carvedilol. Specifically, concentrations of the S-carvedilol enantiomer may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cholestyramine Resin: May decrease the serum concentration of Fluvastatin. Management: Administer fluvastatin at least 1 hour or greater (particularly with extended-release form) before, or at least 4 hours after cholestyramine to minimize the risk for any significant interaction.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ciprofibrate: May enhance the adverse/toxic effect of HMG-CoA Reductase Inhibitors (Statins). Management: Avoid the use of HMG-CoA reductase inhibitors and ciprofibrate if possible. If concomitant therapy is considered, benefits should be carefully weighed against the risks, and patients should be monitored closely for signs/symptoms of muscle toxicity.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cobicistat: May increase the serum concentration of Fluvastatin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Colchicine: May enhance the myopathic (rhabdomyolysis) effect of HMG-CoA Reductase Inhibitors (Statins). Colchicine may increase the serum concentration of HMG-CoA Reductase Inhibitors (Statins).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CycloSPORINE (Systemic): May increase the serum concentration of Fluvastatin. Management: Limit fluvastatin to 20 mg twice daily in patients who are also receiving cyclosporine.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP2C9 Substrates (High risk with Inhibitors): CYP2C9 Inhibitors (Moderate) may decrease the metabolism of CYP2C9 Substrates (High risk with Inhibitors). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cyproterone: May increase the serum concentration of HMG-CoA Reductase Inhibitors (Statins). Management: Avoid use of statins metabolized by CYP3A4 (eg, simvastatin) and consider avoiding fluvastatin as well in patients receiving high dose cyproterone (300 mg/day). Consider use of pravastatin, rosuvastatin, or pitavastatin if statin therapy is needed.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Daclatasvir: May increase the serum concentration of HMG-CoA Reductase Inhibitors (Statins).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">DAPTOmycin: HMG-CoA Reductase Inhibitors (Statins) may enhance the adverse/toxic effect of DAPTOmycin. Specifically, the risk of skeletal muscle toxicity may be increased.  Management: Consider temporarily stopping HMG-CoA reductase inhibitor therapy prior to daptomycin.  If used together, regular (i.e., at least weekly) monitoring of CPK concentrations is recommended.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dronabinol: CYP2C9 Inhibitors (Moderate) may increase the serum concentration of Dronabinol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Elbasvir: May increase the serum concentration of Fluvastatin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Eltrombopag: May increase the serum concentration of OATP1B1/SLCO1B1 Substrates.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Etravirine: May decrease the serum concentration of HMG-CoA Reductase Inhibitors (Statins). This applies to atorvastatin, lovastatin and simvastatin. Conversely, levels of fluvastatin may be increased. Management: Dose adjustment of the HMG-CoA reductase inhibitor may be warranted. No interaction is expected with rosuvastatin, pravastatin, or pitavastatin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fenofibrate and Derivatives: May enhance the adverse/toxic effect of HMG-CoA Reductase Inhibitors (Statins).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fluconazole: May increase the serum concentration of Fluvastatin. Management: Limit fluvastatin maximum  adult dose to 20 mg twice daily, and monitor for toxic effects of fluvastatin (e.g., myalgia, rhabdomyolysis, liver function test abnormalities), during concomitant treatment.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fosphenytoin: May decrease the serum concentration of HMG-CoA Reductase Inhibitors (Statins).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fusidic Acid (Systemic): May enhance the adverse/toxic effect of HMG-CoA Reductase Inhibitors (Statins). Specifically, the risk for muscle toxicities, including rhabdomyolysis may be significantly increased. Management: Avoid concurrent use whenever possible. Use is listed as contraindicated in product characteristic summaries in several countries, although UK labeling suggests that use could be considered under exceptional circumstances and with close supervision.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gemfibrozil: May enhance the myopathic (rhabdomyolysis) effect of Fluvastatin.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Glecaprevir and Pibrentasvir: May increase the serum concentration of HMG-CoA Reductase Inhibitors (Statins). Management: Use the lowest statin dose possible if combined with glecaprevir/pibrentasvir and monitor for increased statin effects/toxicities. Avoid concomitant use with atorva-, simva-, or lovastatin. Limit rosuvastatin to 10 mg daily and reduce pravastatin dose 50%<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Grazoprevir: May increase the serum concentration of Fluvastatin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lanthanum: HMG-CoA Reductase Inhibitors (Statins) may decrease the serum concentration of Lanthanum.  Management: Administer HMG-CoA reductase inhibitors at least two hours before or after lanthanum.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Letermovir: May increase the serum concentration of HMG-CoA Reductase Inhibitors (Statins).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lornoxicam: CYP2C9 Inhibitors (Moderate) may increase the serum concentration of Lornoxicam. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MiFEPRIStone: May increase the serum concentration of Fluvastatin. Management: Use fluvastatin at the lowest recommended dose, and monitor closely for adverse effects (including myopathy), during and in the 2 weeks following mifepristone treatment.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Niacin: May enhance the adverse/toxic effect of HMG-CoA Reductase Inhibitors (Statins).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Niacinamide: May enhance the adverse/toxic effect of HMG-CoA Reductase Inhibitors (Statins).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir: May increase the serum concentration of Fluvastatin. Management: Canadian product labeling recommends use of the lowest fluvastatin dose with this combination.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">PAZOPanib: HMG-CoA Reductase Inhibitors (Statins) may enhance the hepatotoxic effect of PAZOPanib. Specifically, the risk for increased serum transaminase concentrations may be increased.  Management: Simvastatin is specifically implicated in the interaction. There is a lack of data regarding risk with other statins, but caution appears warranted with any statins. Atorvastatin should be avoided due to P-gp inhibition.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phenytoin: May decrease the serum concentration of HMG-CoA Reductase Inhibitors (Statins).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Raltegravir: May enhance the myopathic (rhabdomyolysis) effect of HMG-CoA Reductase Inhibitors (Statins).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Red Yeast Rice: May enhance the adverse/toxic effect of HMG-CoA Reductase Inhibitors (Statins).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Repaglinide: HMG-CoA Reductase Inhibitors (Statins) may increase the serum concentration of Repaglinide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rifamycin Derivatives: May decrease the serum concentration of HMG-CoA Reductase Inhibitors (Statins). Management: Consider use of noninteracting antilipemic agents (note: pitavastatin concentrations may increase with rifamycin treatment).  Monitor for altered HMG-CoA reductase inhibitor effects. Rifabutin and fluvastatin, or possibly pravastatin, may pose lower risk.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rupatadine: May enhance the adverse/toxic effect of HMG-CoA Reductase Inhibitors (Statins). Specifically, the risk for increased CPK and/or other muscle toxicities may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Telaprevir: May increase the serum concentration of Fluvastatin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Teriflunomide: May increase the serum concentration of OATP1B1/SLCO1B1 Substrates.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tetrahydrocannabinol: CYP2C9 Inhibitors (Moderate) may increase the serum concentration of Tetrahydrocannabinol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trabectedin: HMG-CoA Reductase Inhibitors (Statins) may enhance the myopathic (rhabdomyolysis) effect of Trabectedin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin K Antagonists (eg, warfarin): HMG-CoA Reductase Inhibitors (Statins) may enhance the anticoagulant effect of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Voxilaprevir: May increase the serum concentration of HMG-CoA Reductase Inhibitors (Statins). Management: Use the lowest statin dose possible if combined with voxilaprevir and monitor patients for increased statin effects/toxicities. Avoid concomitant use of voxilaprevir with rosuvastatin or pitavastatin, and limit pravastatin doses to 40 mg daily.<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F173501\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;display:inline\">Food reduces rate but not the extent of absorption. Management: Administer without regard to meals.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F173476\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">X (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F173490\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;\">Studies in pregnant women have shown evidence of fetal abnormalities and use is contraindicated in women who are or may become pregnant. There are reports of congenital anomalies following maternal use of HMG-CoA reductase inhibitors in pregnancy; however, maternal disease, differences in specific agents used, and the low rates of exposure limit the interpretation of the available data (Godfrey 2012; Lecarpentier 2012). Cholesterol biosynthesis may be important in fetal development; serum cholesterol and triglycerides increase normally during pregnancy. The discontinuation of lipid lowering medications temporarily during pregnancy is not expected to have significant impact on the long term outcomes of primary hypercholesterolemia treatment.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">The ADA Diabetes guidelines recommends avoiding use of HMG-CoA reductase inhibitors (because they are potentially teratogenic) in sexually active women of childbearing age who are not using reliable contraception (ADA 2018b). If treatment of dyslipidemias is needed in pregnant women or in women of reproductive age, other agents are preferred (Berglund 2012; Stone 2013). The manufacturer recommends administration to women of childbearing potential only when conception is highly unlikely and patients have been informed of potential hazards.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F173491\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if fluvastatin is excreted in breast milk. Due to the potential for serious adverse reactions in a nursing infant, use while breast-feeding is contraindicated by the manufacturer. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F173492\" class=\"block dic drugH1Div\"><span class=\"drugH1\">Dietary Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Generally, patients should be placed on a standard cholesterol-lowering diet and other lifestyle modifications for 3 to 6 months prior to the initiation of drug therapy. The diet should be continued during drug therapy. However, for patients with advanced risk factors (eg, known coronary heart disease), drug therapy may be initiated concurrently with diet modification. </p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Red yeast rice contains variable amounts of several compounds that are structurally similar to HMG-CoA reductase inhibitors, primarily monacolin K (or mevinolin) which is structurally identical to lovastatin; concurrent use of red yeast rice with HMG-CoA reductase inhibitors may increase the incidence of adverse and toxic effects (Lapi 2008; Smith 2003). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F173478\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>2013 ACC/AHA Blood Cholesterol Guideline recommendations (Stone 2013):</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Lipid panel (total cholesterol, HDL, LDL, triglycerides):</b> Baseline lipid panel; fasting lipid profile within 4-12 weeks after initiation or dose adjustment and every 3-12 months (as clinically indicated) thereafter. If 2 consecutive LDL levels are &lt;40 mg/dL, consider decreasing the dose.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Hepatic transaminase levels:</b> Baseline measurement of hepatic transaminase levels (ie, ALT); measure hepatic function if symptoms suggest hepatotoxicity (eg, unusual fatigue or weakness, loss of appetite, abdominal pain, dark-colored urine or yellowing of skin or sclera) during therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>CPK:</b> CPK should not be routinely measured. Baseline CPK measurement is reasonable for some individuals (eg, family history of statin intolerance or muscle disease, clinical presentation, concomitant drug therapy that may increase risk of myopathy). May measure CPK in any patient with symptoms suggestive of myopathy (pain, tenderness, stiffness, cramping, weakness, or generalized fatigue).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Evaluate for new-onset diabetes mellitus during therapy; if diabetes develops, continue statin therapy and encourage adherence to a heart-healthy diet, physical activity, a healthy body weight, and tobacco cessation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">If patient develops a confusional state or memory impairment, may evaluate patient for nonstatin causes (eg, exposure to other drugs), systemic and neuropsychiatric causes, and the possibility of adverse effects associated with statin therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>\n        <i>Manufacturer's labeling:</i></b> Liver enzyme tests (at baseline and  as clinically indicated); lipid panel at four weeks after initiation or dosage titration. Measure CPK when myopathy is being considered; discontinue therapy if markedly elevated CPK levels occur or myopathy is suspected or diagnosed. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49035398\" class=\"block rer drugH1Div\"><span class=\"drugH1\">Reference Range</span>\n    <p style=\"text-indent:0em;\">\n      <b>Treatment goals: </b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>American Association of Clinical Endocrinologists/American College of Endocrinology recommendations (AACE/ACE [Jellinger 2017]):</b> Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Low risk (no risk factors):</i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Non-HDL-C: &lt;160 mg/dL</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">LDL-C: &lt;130 mg/dL</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">ApoB: No recommendation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Moderate (&le;2 risk factors; 10-year risk &lt;10%) or high risk (diabetes; CKD stage 3 to 4; &ge;2 risk factors and 10-year risk 10% to 20%):</i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Non-HDL-C: &lt;130 mg/dL</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">LDL-C: &lt;100 mg/dL</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Apo B: &lt;90 mg/dL</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Very high risk (ACS; carotid/peripheral artery disease; diabetes or CKD stage 3 to 4 with &ge;1 risk factors; HeFH; 10-year risk &gt;20%):</i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Non-HDL-C: &lt;100 mg/dL</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">LDL-C: &lt;70 mg/dL</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Apo B: &lt;80 mg/dL</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Extreme risk (progressive atherosclerotic CVD after achieving LDL</i>\n      <i>&#8208;C &lt;70 mg/dL; CVD and diabetes, CKD stage 3 to 4, or HeFH; history of premature atherosclerotic CVD (&lt;55 years [males]; &lt;65 years [females]):</i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Non-HDL-C: &lt;80 mg/dL</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">LDL-C: &lt;55 mg/dL</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Apo B: &lt;70 mg/dL</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>National Lipid Association Dyslipidemia recommendations (NLA [Jacobson 2015]):</b> Adults &ge;20 years:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Low-, moderate-, or high-risk patient categories: </i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Non-HDL-C &lt;130 mg/dL</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">LDL-C &lt;100 mg/dL</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Apo B &lt;90 mg/dL (Apo B is a secondary, optional target of treatment for patients that have achieved treatment goals for non-HDL-C and LDL-C)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Note: </b>For patients with diabetes plus 1 major ASCVD risk factor (ie, <i>high risk </i>category), treating to a non-HDL-C goal of &lt;100 mg/dL (LDL-C of &lt;70 mg/dL) may be considered.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Very high-risk patient category:</i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Non-HDL-C &lt;100 mg/dL</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">LDL-C &lt;70 mg/dL</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Apo B &lt;80 mg/dL (Apo B is a secondary, optional target of treatment for patients that have achieved treatment goals for non-HDL-C and LDL-C)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F173468\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Acts by competitively inhibiting 3-hydroxyl-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, the enzyme that catalyzes the reduction of HMG-CoA to mevalonate; this is an early rate-limiting step in cholesterol biosynthesis. HDL is increased while total, LDL, and VLDL cholesterols; apolipoprotein B; and plasma triglycerides are decreased. In addition to the ability of HMG-CoA reductase inhibitors to decrease levels of high-sensitivity C-reactive protein (hsCRP), they also possess pleiotropic properties including improved endothelial function, reduced inflammation at the site of the coronary plaque, inhibition of platelet aggregation, and anticoagulant effects (de Denus 2002; Ray 2005).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F173486\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Onset of action: Peak effect: Maximal LDL-C reductions achieved within 4 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: V<sub>dss</sub>: 0.35 L/kg </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: 98% </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Hepatic to inactive and active metabolites (oxidative metabolism via CYP2C9 [~75%], CYP2C8 [~5%], and CYP3A4 [~20%] isoenzymes); active forms do not circulate systemically; extensive (saturable) first-pass hepatic extraction </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Bioavailability: Absolute: Immediate-release: 24%; Extended-release: ~29% (increased by ~50% when administered with a high-fat meal)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: Immediate-release: ~3 hours; Extended-release: 7.3 to 10.5 hours (due to prolonged absorption time) (Barilla 2004) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Immediate-release: &lt;1 hour (delayed more than 2-fold when administered with food as compared to administering 4 hours after the evening meal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Extended-release: ~3 hours (minimally affected by low-fat meals; however, with a high-fat meal, delayed by 2-fold)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Feces (~90%; &lt;2% unchanged); urine (~5%) </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F173489\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Fluvastatin Sodium Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mg (90): $449.81</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">40 mg (90): $449.81</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, 24-hour</b> (Fluvastatin Sodium ER Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">80 mg (30): $262.87</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, 24-hour</b> (Lescol XL Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">80 mg (30): $387.56</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F173493\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Cranoc (DE);</li>\n      <li>Digaril (ES);</li>\n      <li>Fluvas (BD);</li>\n      <li>Fractal (FR);</li>\n      <li>Fractal LP (FR);</li>\n      <li>Lescol (AE, AT, AU, BB, BE, BH, BM, BR, BS, BZ, CH, CN, CY, CZ, DK, EE, EG, FI, FR, GB, GR, GY, HN, HR, HU, IE, IL, IQ, IR, IT, JM, JO, KR, KW, LB, LU, LY, MT, MX, MY, NL, NO, NZ, OM, PE, PH, PL, PT, QA, RO, RU, SA, SE, SG, SI, SK, SR, SY, TH, TR, TT, TW, VE, YE);</li>\n      <li>Lescol LP (FR);</li>\n      <li>Lescol XL (AE, AR, AU, BG, BH, CO, CY, EC, GB, HK, HR, ID, JO, KR, KW, LB, LT, LV, MT, MX, MY, PE, PH, QA, RO, SA, SG, SI, SK, TH, TW, VN);</li>\n      <li>Leskol XL (UA);</li>\n      <li>Lesterol (BD);</li>\n      <li>Lochol (JP);</li>\n      <li>Locol (DE);</li>\n      <li>Luvinsta (MT, VN);</li>\n      <li>Luvinsta SR (MT);</li>\n      <li>Vaditon (ES);</li>\n      <li>Vastin (AU);</li>\n      <li>Xilep (KR);</li>\n      <li>Xilep XL (KR)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    American Diabetes Association (ADA). 9. Cardiovascular disease and risk management: standards of medical care in diabetes-2018. <i>Diabetes Care</i>. 2018a;41(suppl 1): S86-S104. doi: 10.2337/dc18-S009.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluvastatin-drug-information/abstract-text/29222380/pubmed\" target=\"_blank\" id=\"29222380\">29222380</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"29222384\"></a>American Diabetes Association (ADA). 13. Management of diabetes in pregnancy: standards of medical care in diabetes-2018. <i>Diabetes Care</i>. 2018b;41(suppl 1):S137-S143. doi: 10.2337/dc18-S013.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluvastatin-drug-information/abstract-text/29222384/pubmed\" target=\"_blank\" id=\"29222384\">29222384</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Barilla D, Prasad P, Hubert M, Gumbhir-Shah K. Steady-state pharmacokinetics of fluvastatin in healthy subjects following a new extended release fluvastatin tablet, Lescol XL. <i>Biopharm Drug Dispos</i>. 2004;25(2):51-59.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluvastatin-drug-information/abstract-text/14872552/pubmed\" target=\"_blank\" id=\"14872552\">14872552</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Berglund L, Brunzell JD, Goldberg AC, et al, &ldquo;Evaluation and Treatment of Hypertriglyceridemia: An Endocrine Society Clinical Practice Guideline,&rdquo; <i>J Clin Endocrinol Metab</i>, 2012, 97(9):2969-89.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluvastatin-drug-information/abstract-text/22962670/pubmed\" target=\"_blank\" id=\"22962670\">22962670</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Canadian Diabetes Association Clinical Practice Guidelines Expert Committee, &quot;Canadian Diabetes Association 2013 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada,&quot; <i>Can J Diabetes</i>, 2013, 35(Suppl 1):1-212.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Castro C and Gourley M, &quot;Diagnosis and Treatment of Inflammatory Myopathy: Issues and Management,&quot; <i>Ther Adv Musculoskelet Dis</i>, 2012, 4(2):111-20.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluvastatin-drug-information/abstract-text/22870499/pubmed\" target=\"_blank\" id=\"22870499\">22870499</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    de Denus S and Spinler SA, &ldquo;Early Statin Therapy for Acute Coronary Syndromes,&rdquo; <i>Ann Pharmacother</i>, 2002, 36(11):1749-58.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluvastatin-drug-information/abstract-text/12398573/pubmed\" target=\"_blank\" id=\"12398573\">12398573</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fernandez AB, Karas RH, Alsheikh-Ali AA, et al, &ldquo;Statins and Interstitial Lung Disease: A Systematic Review of the Literature and of Food and Drug Administration Adverse Event Reports,&rdquo; <i>Chest</i>, 2008, 134(4):824-30.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluvastatin-drug-information/abstract-text/18689579/pubmed\" target=\"_blank\" id=\"18689579\">18689579</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fihn SD, Gardin JM, Abrams J, et al, &ldquo;2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons,&rdquo; <i>Circulation</i>, 2012, 126(25):3097-137.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluvastatin-drug-information/abstract-text/23166211/pubmed\" target=\"_blank\" id=\"23166211\">23166211</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fleisher LA, Fleischmann KE, Auerbach AD, et al. 2014 ACC/AHA guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. <i>Circulation</i>. 2014;130(24):e278-e333.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluvastatin-drug-information/abstract-text/25085961/pubmed\" target=\"_blank\" id=\"25085961\">25085961</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fonarow GC, French WJ, Parsons LS, et al, &ldquo;Use of Lipid-Lowering Medications at Discharge in Patients With Acute Myocardial Infarction: Data From the National Registry of Myocardial Infarction 3,&rdquo; <i>Circulation</i>, 2001, 103(1):38-44.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluvastatin-drug-information/abstract-text/11136683/pubmed\" target=\"_blank\" id=\"11136683\">11136683</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Godfrey LM, Erramouspe J, and Cleveland KW, &quot;Teratogenic Risk of Statins in Pregnancy,&quot; <i>Ann Pharmacother</i>, 2012, 46(10):1419-24.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluvastatin-drug-information/abstract-text/23032657/pubmed\" target=\"_blank\" id=\"23032657\">23032657</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Heeschen C, Hamm CW, Laufs U, et al, &ldquo;Withdrawal of Statins Increases Event Rates in Patients With Acute Coronary Syndromes,&rdquo; <i>Circulation</i>, 2002, 105(12):1446-52.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluvastatin-drug-information/abstract-text/11914253/pubmed\" target=\"_blank\" id=\"11914253\">11914253</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hillis LD, Smith PK, Anderson JL, et al. 2011 ACCF/AHA guideline for coronary artery bypass graft surgery: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines [published correction appears in <i>Circulation</i>. 2012;126(7):e105]. <i>Circulation</i>. 2011;124(23):2610-2642. doi: 10.1161/CIR.0b013e31823b5fee.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluvastatin-drug-information/abstract-text/22064600/pubmed\" target=\"_blank\" id=\"22064600\">22064600</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Huang CY, Chung SD, Kao LT, Lin HC, Wang LH. Statin use is associated with bladder pain syndrome/interstitial cystitis: a population-based case-control study. <i>Urol Int</i>. 2015;95(2):227-232.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluvastatin-drug-information/abstract-text/26184102/pubmed\" target=\"_blank\" id=\"26184102\">26184102</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society [published online March 28, 2014]. <i>Circulation</i>.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluvastatin-drug-information/abstract-text/24682347/pubmed\" target=\"_blank\" id=\"24682347\">24682347</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jacobson TA, Ito MK, Maki KC, et al. National lipid association recommendations for patient-centered management of dyslipidemia: part 1--full report. <i>J Clin Lipidol</i>. 2015;9(2):129-169. doi: 10.1016/j.jacl.2015.02.003.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluvastatin-drug-information/abstract-text/25911072/pubmed\" target=\"_blank\" id=\"25911072\">25911072</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jellinger PS, Handelsman Y, Rosenblit PD, et al. American Association of Clinical Endocrinologists and American College of Endocrinology guidelines for management of dyslipidemia and prevention of cardiovascular disease. <i>Endocr Pract</i>. 2017;23(suppl 2):1-87. doi: 10.4158/EP171764.APPGL.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluvastatin-drug-information/abstract-text/28437620/pubmed\" target=\"_blank\" id=\"28437620\">28437620</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"24788967\"></a>Kernan WN, Ovbiagele B, Black HR, et al; American Heart Association Stroke Council; Council on Cardiovascular and Stroke Nursing; Council on Clinical Cardiology; Council on Peripheral Vascular Disease. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association [published correction appears in <i>Stroke</i>. 2015;46(2):e54]. <i>Stroke</i>. 2014;45(7):2160-2236. doi: 10.1161/STR.0000000000000024.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluvastatin-drug-information/abstract-text/24788967/pubmed\" target=\"_blank\" id=\"24788967\">24788967</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kondo C, Atsukawa M, Tsubota A, et al. An open-label randomized controlled study of pegylated interferon/ribavirin combination therapy for chronic hepatitis C with versus without fluvastatin. <i>J Viral Hepatitis</i>. 2012;19(9):615-622.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluvastatin-drug-information/abstract-text/22863265/pubmed\" target=\"_blank\" id=\"22863265\">22863265</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kulik A, Ruel M, Jneid H, et al. Secondary prevention after coronary artery bypass graft surgery: a scientific statement from the American Heart Association. <i>Circulation</i>. 2015;131(10):927-964. doi: 10.1161/CIR.0000000000000182.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluvastatin-drug-information/abstract-text/25679302/pubmed\" target=\"_blank\" id=\"25679302\">25679302</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kurincic ST, Lesnicar G, Poljak M, et al. Impact of Added Fluvastatin to Standard-of-Care Treatment on Sustained Virological Response in Na&iuml;ve Chronic Hepatitis C Patients Infected with Genotypes 1 and 3. <i>Interviriology</i> 2014;57(1):23-30.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluvastatin-drug-information/abstract-text/24080608/pubmed\" target=\"_blank\" id=\"24080608\">24080608</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lapi F, Gallo E, Bernasconi S, et al. Myopathies associated with red yeast rice and liquorice: spontaneous reports from the Italian Surveillance System of Natural Health Products. <i>Br J Clin Pharmacol</i>. 2008;66(4):572-574.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluvastatin-drug-information/abstract-text/18637891/pubmed\" target=\"_blank\" id=\"18637891\">18637891</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    LaRosa JC, Grundy SM, Waters DD, et al, &ldquo;Intensive Lipid Lowering With Atorvastatin in Patients With Stable Coronary Disease,&rdquo; <i>N Engl J Med</i>, 2005, 352(14):1425-35.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluvastatin-drug-information/abstract-text/15755765/pubmed\" target=\"_blank\" id=\"15755765\">15755765</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lecarpentier E, Morel O, Fournier T, et al, &quot;Statins and Pregnancy: Between Supposed Risks and Theoretical Benefits,&quot; <i>Drugs</i>, 2012, 72(6):773-88.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluvastatin-drug-information/abstract-text/22480340/pubmed\" target=\"_blank\" id=\"22480340\">22480340</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    LeManach Y, Godet G, Coriat P, et al, &ldquo;The Impact of Postoperative Discontinuation or Continuation of Chronic Statin Therapy on Cardiac Outcome After Major Vascular Surgery,&rdquo; <i>Anesth Analg</i>, 2007, 104(6):1326-33.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluvastatin-drug-information/abstract-text/17513620/pubmed\" target=\"_blank\" id=\"17513620\">17513620</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lescol/Lescol XL (fluvastatin) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corp; August 2017.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluvastatin-drug-information/abstract-text/17513620/pubmed\" target=\"_blank\" id=\"17513620\">17513620</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    McPherson R, Frohlich J, Fodor G, et al, &ldquo;Canadian Cardiovascular Society Position Statement--Recommendations for the Diagnosis and Treatment of Dyslipidemia and Prevention of Cardiovascular Disease,&rdquo; [published correction appears in <i>Can J Cardiol</i>. 2006, 22(12):1077]. <i>Can J Cardiol</i>. 2006;22(11):913-927.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluvastatin-drug-information/abstract-text/16971976/pubmed\" target=\"_blank\" id=\"16971976\">16971976</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &ldquo;MRC/BHF Heart Protection Study of Cholesterol Lowering With Simvastatin in 20,536 High-Risk Individuals: A Randomised Placebo-Controlled Trial. Heart Protection Study Collaborative Group,&rdquo; <i>Lancet</i>, 2002, 360(9326):7-22.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluvastatin-drug-information/abstract-text/12114036/pubmed\" target=\"_blank\" id=\"12114036\">12114036</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pasternak RC, Smith SC Jr, Bairey-Merz CN, et al, &ldquo;ACC/AHA/NHLBI Clinical Advisory on the Use and Safety of Statins,&rdquo; Stroke, 2002, 33(9):2337-41. Available at http://stroke.ahajournals.org/cgi/content/short/33/9/233712215610</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pearson TA, Mensah GA, Alexander RW, et al, &ldquo;Markers of Inflammation and Cardiovascular Disease: Application to Clinical and Public Health Practice: A Statement for Healthcare Professionals From the Centers for Disease Control and Prevention and the American Heart Association,&rdquo; <i>Circulation</i>, 2003, 107(3):499-511.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluvastatin-drug-information/abstract-text/12551878/pubmed\" target=\"_blank\" id=\"12551878\">12551878</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Phillips BG, Yim JM, Brown EJ Jr, et al, &ldquo;Pharmacologic Profile of Survivors of Acute Myocardial Infarction at United States Academic Hospitals,&rdquo; <i>Am Heart J</i>, 1996, 131(5):872-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluvastatin-drug-information/abstract-text/8615304/pubmed\" target=\"_blank\" id=\"8615304\">8615304</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Poldermans D, Bax JJ, Kertai MD, et al, &ldquo;Statins Are Associated With a Reduced Incidence of Perioperative Mortality in Patients Undergoing Major Noncardiac Vascular Surgery,&rdquo; <i>Circulation</i>, 2003, 107(14):1848-51.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluvastatin-drug-information/abstract-text/12695283/pubmed\" target=\"_blank\" id=\"12695283\">12695283</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ray KK and Cannon CP. The potential relevance of the multiple lipid-independent (pleiotropic) effects of statins in the management of acute coronary syndromes. <i>J Am Coll Cardiol</i>. 2005;46(8):1425-1433.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluvastatin-drug-information/abstract-text/16226165/pubmed\" target=\"_blank\" id=\"16226165\">16226165</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ridker PM, Danielson E, Fonseca FAH, et al, &ldquo;Rosuvastatin to Prevent Vascular Events in Men and Women With Elevated C-Reactive Protein,&rdquo; <i>N Engl J Med</i>, 2008, 359(21):2195-207.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluvastatin-drug-information/abstract-text/18997196/pubmed\" target=\"_blank\" id=\"18997196\">18997196</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sever PS, Dahlof B, Poulter NR, et al, &ldquo;Prevention of Coronary and Stroke Events With Atorvastatin in Hypertensive Patients Who Have Average or Lower-Than-Average Cholesterol Concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial - Lipid Lowering Arm (ASCOT-LLA): A Multicentre Randomised Controlled Trial,&rdquo; <i>Lancet</i>, 2003, 361(9364):1149-58.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluvastatin-drug-information/abstract-text/12686036/pubmed\" target=\"_blank\" id=\"12686036\">12686036</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shepherd J, Cobbe SM, Ford I, et al, &ldquo;Prevention of Coronary Heart Disease With Pravastatin in Men With Hypercholesterolemia. West of Scotland Coronary Prevention Study Group,&rdquo; <i>N Engl J Med</i>, 1995, 333(20):1301-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluvastatin-drug-information/abstract-text/7566020/pubmed\" target=\"_blank\" id=\"7566020\">7566020</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Smith DJ, Olive KE. Chinese red rice-induced myopathy. <i>South Med J</i>. 2003;96(12):1265-1267.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluvastatin-drug-information/abstract-text/14696880/pubmed\" target=\"_blank\" id=\"14696880\">14696880</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Stone NJ, Robinson J, Lichtenstein AH, et al, 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines [published online ahead of print November 12, 2013].<i>Circulation</i>. 2013; doi: 10.1161/01.cir.0000437738.63853.7a.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tonelli M, Wanner C; for the Kidney Disease: Improving Global Outcomes Lipid Guideline Development Work Group Members. Lipid Management in Chronic Kidney Disease: Synopsis of the Kidney Disease: Improving Global Outcomes 2013 Clinical Practice Guideline [published online ahead of print]. <i>Ann Intern Med</i>. 2013.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluvastatin-drug-information/abstract-text/24323134/pubmed\" target=\"_blank\" id=\"24323134\">24323134</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 8473 Version 184.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F173506\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F173507\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F173548\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F173511\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F2931789\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F173512\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F173513\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F173514\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adjustment for Toxicity\" href=\"#F22888099\" class=\"outlineLink\">Dosing: Adjustment for Toxicity</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F173480\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F173465\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F173484\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F173483\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F50287199\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F173556\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F173472\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F173487\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F173469\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F173542\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F173474\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F173501\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F173476\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F173490\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F173491\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dietary Considerations\" href=\"#F173492\" class=\"outlineLink\">Dietary Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F173478\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Reference Range\" href=\"#F49035398\" class=\"outlineLink\">Reference Range</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F173468\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F173486\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F173489\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F173493\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/8473|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=fluvastatin-patient-drug-information\" class=\"drug drug_patient\">Fluvastatin: Patient drug information</a></li><li><a href=\"topic.htm?path=fluvastatin-pediatric-drug-information\" class=\"drug drug_pediatric\">Fluvastatin: Pediatric drug information</a></li></ul></div></div>","javascript":null}